Fig. 9: CD5L promotes neutrophil chemotaxis via CXCL1, and neutrophil activation.

a Quantification of inflammatory chemokines in WT and CD5L⁻ mice at indicated time points after mid-grade CLP, using bead-based multiplex immunoassays. b WT mice subjected to high-grade CLP were IV-injected with 2.5 mg/kg of rCD5L, or PBS (untreated), 3 h later. Inflammatory chemokines were quantified 6 h post-CLP. c CXCL1 concentrations in WT and CD5L⁻ mice after mid-grade CLP (extracted from data presented in a). d CXCL1 concentrations in untreated and IV-treated WT mice after high-grade CLP (extracted from data presented in b). a–d Pooled data from at least 2 independent experiments, analyzed by two-tailed Mann-Whitney test. a, c Mice per group: Peritoneum: 4 WT and 4 CD5L⁻ at 0 h, 4 WT, and 3 CD5L⁻ at 3 h, 6 WT, and 6 CD5L⁻ at 6 h; Blood, 9 WT and 9 CD5L⁻ at 0 h, 3 WT, and 3 CD5L⁻ at 3 h, 8 WT and 5 CD5L⁻ at 6 h. b, d Mice per group: 6 in untreated, 5 in rCD5L IV-treated. e CD5L⁻ mice were injected IV with rCD5L (2.5 mg/kg) 3 h after mid-grade CLP and peritoneal cells were recovered 3 h later. Percentage of CD5L-bound cells within CD45^- cells; neutrophils (CD45⁺CD11b⁺Ly6G⁺), macrophages (CD45⁺CD11b⁺F4/80⁺), other CD11b⁺ (CD45⁺CD11b⁺F4/80^-Ly6G^-), B cells (CD45⁺B220⁺), and T cells (CD45⁺CD3⁺). f MFI values of the CXCL1 channel within CXCL1⁺ cells in each subset defined in e. e, f Pooled data from 2 independent experiments, analyzed by two-way ANOVA. Mice per group: 5 untreated and 6 rCD5L-treated. Ly6G and CD11b MFI in neutrophils collected from the peritoneal cavity of rCD5L IP- (left panel) or IV-treated (right panel) WT mice, after high-grade CLP (g), or WT vs. CD5L⁻ mice after mid-grade CLP (h). Mice per group: IP treatment: 3 at 6 h, 4 at 24 h; IV treatment: 6 at 6 h, 6 at 24 h (g); IP and IV treatment: 4 (h). Pooled data from 2 independent experiments, statistical comparisons between groups were established by two-tailed unpaired t-tests with Welch’s correction.